The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

GyneCure     1-[2-[(2-chlorothiophen-3- yl)methoxy]-2-(2...

Synonyms: Vagistat, Zoniden, Fungibacid, Tioconazol, Trosyd, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Vagistat-1

  • After vaginal insertion of a 300-mg ovule of tioconazole in 10 patients with vaginal candidiasis, the mean concentration in plasma was 21.2 ng/ml (range, 10.6 to 35.8 ng/ml) at 8 h and was not measurable at 24 h in 9 of 10 patients [1].
  • Preliminary studies in other clinical areas suggest tioconazole may be useful for treating onychomycosis (in a special nail formulation), napkin-rash due to Candida albicans, impetigo, and vaginal trichomoniasis, although comparative studies are needed in each of these settings to clearly assess its relative place in therapy [2].
  • Tioconazole. A review of its antimicrobial activity and therapeutic use in superficial mycoses [2].
  • Single-dose tioconazole compared with 3-day clotrimazole treatment in vulvovaginal candidiasis [3].
  • In contrast to C. albicans, the Gram-positive bacterium, Staphylococcus aureus H, which lacks membrane sterols, showed no trailing endpoints with tioconazole after either shaken or static incubation [4].
 

High impact information on Vagistat-1

  • General equations and data analysis methods are presented to relate mobilities to equilibrium constants in simple and competitive binding equilibria and used to determine thermodynamic parameters for host-guest complexation of tioconazole enantiomers with a range of cyclodextrin selectors [5].
  • Thus, tioconazole is an effective and well tolerated treatment for vaginal candidiasis and superficial fungal infections of the skin [2].
  • At a concentration of 3.8 X 10(-5) M, tioconazole, like miconazole, caused rapid 2- to 3-log reductions in CFU per milliliter when added to late-logarithmic-phase Candida albicans or Candida parapsilosis cells [6].
  • Bioluminescent assays of fungal ATP in cultures of Candida albicans exposed to tioconazole and ketoconazole demonstrated that intracellular ATP levels were directly related to cell viability [7].
  • Studies of the kinetics of killing indicated that the drugs studied could kill under conditions used for the MFC determination and that tioconazole and ketoconazole could kill particularly rapidly [8].
 

Chemical compound and disease context of Vagistat-1

 

Biological context of Vagistat-1

 

Associations of Vagistat-1 with other chemical compounds

 

Gene context of Vagistat-1

  • Effects of tioconazole on parturition and serum levels of 17 beta-oestradiol, progesterone, LH and PRL in the rat [14].
  • Development and optimisation of a high-performance liquid chromatographic assay for tioconazole and its potential impurities. Part II. Selection of detection conditions for potential impurities [20].
 

Analytical, diagnostic and therapeutic context of Vagistat-1

References

  1. Systemic absorption and persistence of tioconazole in vaginal fluid after insertion of a single 300-mg tioconazole ovule. Houang, E.T., Lawrence, A.G. Antimicrob. Agents Chemother. (1985) [Pubmed]
  2. Tioconazole. A review of its antimicrobial activity and therapeutic use in superficial mycoses. Clissold, S.P., Heel, R.C. Drugs (1986) [Pubmed]
  3. Single-dose tioconazole compared with 3-day clotrimazole treatment in vulvovaginal candidiasis. Stein, G.E., Gurwith, D., Mummaw, N., Gurwith, M. Antimicrob. Agents Chemother. (1986) [Pubmed]
  4. Correlation of inhibition of sterol synthesis with growth-inhibitory action of imidazole antimycotics in Candida albicans. Nicholas, R.O., Kerridge, D. J. Antimicrob. Chemother. (1989) [Pubmed]
  5. Capillary electrophoresis with chiral selectors: optimization of separation and determination of thermodynamic parameters for binding of tioconazole enantiomers to cyclodextrins. Penn, S.G., Bergström, E.T., Goodall, D.M. Anal. Chem. (1994) [Pubmed]
  6. Fungicidal activity of tioconazole in relation to growth phase of Candida albicans and Candida parapsilosis. Beggs, W.H. Antimicrob. Agents Chemother. (1984) [Pubmed]
  7. Direct membrane-damaging effect of ketoconazole and tioconazole on Candida albicans demonstrated by bioluminescent assay of ATP. Anséhn, S., Nilsson, L. Antimicrob. Agents Chemother. (1984) [Pubmed]
  8. Inhibition and killing of Candida albicans in vitro by five imidazoles in clinical use. Lefler, E., Stevens, D.A. Antimicrob. Agents Chemother. (1984) [Pubmed]
  9. Anti-inflammatory and anti-itch activity of sertaconazole nitrate. Liebel, F., Lyte, P., Garay, M., Babad, J., Southall, M.D. Arch. Dermatol. Res. (2006) [Pubmed]
  10. Treatment of dermatomycoses with topical tioconazole and miconazole. Fredriksson, T. Dermatologica (1983) [Pubmed]
  11. Topical tioconazole versus systemic ketoconazole treatment of vaginal candidiasis. Rohde-Werner, H. J. Int. Med. Res. (1984) [Pubmed]
  12. Comparative and non-comparative studies of the efficacy and tolerance of tioconazole cream 1% versus another imidazole and/or placebo in neonates and infants with candidal diaper rash and/or impetigo. Gibbs, D.L., Kashin, P., Jevons, S. J. Int. Med. Res. (1987) [Pubmed]
  13. Open comparison of the efficacy, toleration and safety of tioconazole cream and econazole ovules used in the 3-day treatment of patients with vaginal candidiasis. Cohen, J. Gynäkologische Rundschau. (1983) [Pubmed]
  14. Effects of tioconazole on parturition and serum levels of 17 beta-oestradiol, progesterone, LH and PRL in the rat. Latrille, F., Perraud, J., Stadler, J., Monro, A.M., Sutter, B.C. Biochem. Pharmacol. (1987) [Pubmed]
  15. A comparative study of 1-substituted imidazole and 1,2,4-triazole antifungal compounds as inhibitors of testosterone hydroxylations catalysed by mouse hepatic microsomal cytochromes P-450. Ballard, S.A., Lodola, A., Tarbit, M.H. Biochem. Pharmacol. (1988) [Pubmed]
  16. Antifungal relative inhibition factors: BAY l-9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole and vibunazole (BAY n-7133) compared in vitro with nine established antifungal agents. Odds, F.C., Webster, C.E., Abbott, A.B. J. Antimicrob. Chemother. (1984) [Pubmed]
  17. In vitro antimicrobial activity of tioconazole and its concentrations in vaginal fluids following topical (vagistat-1 6.5%) application. Jones, R.N., Bale, M.J., Hoban, D., Erwin, M.E. Diagn. Microbiol. Infect. Dis. (1993) [Pubmed]
  18. A study of 72 patients with contact allergy to tioconazole. Heikkilä, H., Stubb, S., Reitamo, S. Br. J. Dermatol. (1996) [Pubmed]
  19. Role of the ABC transporter TruMDR2 in terbinafine, 4-nitroquinoline N-oxide and ethidium bromide susceptibility in Trichophyton rubrum. Fachin, A.L., Ferreira-Nozawa, M.S., Maccheroni, W., Martinez-Rossi, N.M. J. Med. Microbiol. (2006) [Pubmed]
  20. Development and optimisation of a high-performance liquid chromatographic assay for tioconazole and its potential impurities. Part II. Selection of detection conditions for potential impurities. Wright, A.G., Berridge, J.C., Fell, A.F. The Analyst. (1989) [Pubmed]
  21. Effect of investigator bias on clinical trials. Smith, E.B. Archives of dermatology. (1989) [Pubmed]
  22. In-vivo selection of an azole-resistant petite mutant of Candida glabrata. Bouchara, J.P., Zouhair, R., Le Boudouil, S., Renier, G., Filmon, R., Chabasse, D., Hallet, J.N., Defontaine, A. J. Med. Microbiol. (2000) [Pubmed]
 
WikiGenes - Universities